Marco Meglio

January 11, 2024

AXIOMATIC-SSP is considered the largest clinical trial of activated factor XIa inhibition added to standard antiplatelet therapy for secondary stroke prevention.

December 07, 2023

Among study participants with migraine, investigators observed consistent and persistent device efficacy for pain relief, pain freedom, and functional disability freedom.

December 07, 2023

Ubrogepant 100 mg taken during the migraine prodrome significantly reduced onset of moderate or severe headache for 24 hours after study-drug dose.

October 26, 2023

Findings from phase 3 ACCORD clinical trial demonstrated rapid and sustained clinical response in patients with Alzheimer disease agitation with no new safety signals reported.

October 20, 2023

Ailiani, director of MedStar Georgetown Headache Center, focuses on optimizing treatment with CGRP inhibitors and where research on PACAP-targeting agents stands now.

August 17, 2023

Various illicit substances were detected in urine assays of 1 in 10 patients admitted to cardiac intensive care, according to findings of new French study.

August 14, 2023

The device from Nexalin Technology outperformed placebo on key measures of pain relief, sleep quality, anxiety, and quality of life.

May 25, 2023

Bayer's investigational FXIa inhibitor is currently being studied in a large-scale phase 3 development program expected to enroll more than 27 000 participants.

January 11, 2023

Approval of lecanemab under FDA's accelerated pathway requires the company to provide phase 4 study evidence to confirm the agent's clinical effect.